Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis ; volume:7 ; number:1 ; day:15 ; month:12 ; year:2017 ; pages:1-12 ; date:12.2017
Scientific reports ; 7, Heft 1 (15.12.2017), 1-12, 12.2017
- Creator
-
Cerruti, Fulvia
Jocollè, Genny
Salio, Chiara
Oliva, Laura
Paglietti, Luca
Alessandria, Beatrice
Mioletti, Silvia
Donati, Giovanni
Numico, Gianmauro
Cenci, Simone
Cascio, Paolo
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-017-17977-9
- URN
-
urn:nbn:de:101:1-2019070801363551342002
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cerruti, Fulvia
- Jocollè, Genny
- Salio, Chiara
- Oliva, Laura
- Paglietti, Luca
- Alessandria, Beatrice
- Mioletti, Silvia
- Donati, Giovanni
- Numico, Gianmauro
- Cenci, Simone
- Cascio, Paolo
- SpringerLink (Online service)
Other Objects (12)
Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment
Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity
Bortezomib sensitizes neuroblastoma for TRAIL-induced apoptosis
ADAM10 mediates malignant pleural mesothelioma invasiveness
Early detection of malignant pleural mesothelioma
KRAS signaling in malignant pleural mesothelioma
Molecular biological analysis of malignant pleural mesothelioma
Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths
Genomic landscape of pleural and peritoneal mesothelioma tumours
Correlation between pleural fluid cytology and magnitude of pleural invasion in patients with malignant pleural mesothelioma
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment
Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity
Bortezomib sensitizes neuroblastoma for TRAIL-induced apoptosis
ADAM10 mediates malignant pleural mesothelioma invasiveness
Early detection of malignant pleural mesothelioma
KRAS signaling in malignant pleural mesothelioma
Molecular biological analysis of malignant pleural mesothelioma
Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths
Genomic landscape of pleural and peritoneal mesothelioma tumours
Correlation between pleural fluid cytology and magnitude of pleural invasion in patients with malignant pleural mesothelioma
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment
Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity
Bortezomib sensitizes neuroblastoma for TRAIL-induced apoptosis
ADAM10 mediates malignant pleural mesothelioma invasiveness
Early detection of malignant pleural mesothelioma
KRAS signaling in malignant pleural mesothelioma
Molecular biological analysis of malignant pleural mesothelioma
Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths
Genomic landscape of pleural and peritoneal mesothelioma tumours
Correlation between pleural fluid cytology and magnitude of pleural invasion in patients with malignant pleural mesothelioma
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy